Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJingjing DengPWPing WangYTYing Tian

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows that MRD negativity improves survival in primary plasma cell leukemia, indicating ASCT remains beneficial despite new therapies.

Key Points

  • MRD negativity correlates with improved progression-free survival and overall survival in primary plasma cell leukemia.
  • Statistical analyses revealed significant survival rates with survival predictors identified via Cox regression.
  • Improved outcomes observed through autologous hematopoietic stem cell transplantation, even with novel agents in use.
  • Propensity-score matching confirms ASCT as a preferred therapy, enhancing remission rates in pPCL patients.

Cite This Study

Deng et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4d2https://doi.org/10.1182/blood-2025-7564
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia2025
  2. 2Outcomes of pPCL Diagnosed Using the IMWG 2021 Consensus Definition: A Retrospective Multicenter Analysis2026
  3. 3Plasma cell leukemia: A single institution review of cases2025
  4. 4Dynamic evolution of minimal residual disease and normal plasma cells following autologous stem cell transplantation in multiple myeloma2025
  5. 5Multiple myeloma with ≥1% circulating plasma cells in peripheral blood has a poor prognosis2025